Regeneron Pharmaceuticals, Inc. Stock Sao Paulo

Equities

REGN34

BRREGNBDR005

Biotechnology & Medical Research

Market Closed - Sao Paulo 02:23:40 2024-07-16 pm EDT 5-day change 1st Jan Change
99.06 BRL +26.37% Intraday chart for Regeneron Pharmaceuticals, Inc. +3.08% +45.44%
Sales 2024 * 13.83B 75.03B Sales 2025 * 14.95B 81.12B Capitalization 118B 641B
Net income 2024 * 4.05B 21.99B Net income 2025 * 4.45B 24.14B EV / Sales 2024 * 7.91 x
Net cash position 2024 * 8.76B 47.52B Net cash position 2025 * 14.53B 78.82B EV / Sales 2025 * 6.93 x
P/E ratio 2024 *
32.3 x
P/E ratio 2025 *
29 x
Employees 13,677
Yield 2024 *
-
Yield 2025 *
-
Free-Float 78.45%
More Fundamentals * Assessed data
Dynamic Chart
UBS Raises Price Target on Regeneron Pharmaceuticals to $1,250 From $1,124, Maintains Buy Rating MT
Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183 MT
Barclays Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,050 MT
RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,232 From $1,229, Keeps Outperform Rating MT
Regeneron Expects Earnings Hit After $24 Million R&D Charge DJ
Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval MT
Sanofi obtains EU approval for Dupixent RE
Sanofi, Regeneron Get EU Approval for Dupixent to Treat Respiratory Disease DJ
EU approves Sanofi's Dupixent for 'smoker's lungs' RE
Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,190,564, According to a Recent SEC Filing MT
Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 1000 Dynamic Index CI
Regeneron Gets European Health Agency Committee's Positive Opinion for Conditional Marketing Authorization of Lymphoma Drug Candidate Odronextamab MT
Regeneron Wins CHMP Backing of Lymphoma Drug Odronextamab DJ
Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma CI
More news
1 day+26.37%
1 week+3.08%
Current month+2.11%
1 month+6.34%
3 months+26.68%
6 months+32.88%
Current year+45.44%
More quotes
1 week
98.14
Extreme 98.14
100.60
1 month
93.18
Extreme 93.18
100.60
Current year
72.00
Extreme 72
100.60
1 year
56.94
Extreme 56.94
100.60
3 years
46.69
Extreme 46.6942
100.60
5 years
19.07
Extreme 19.0717
100.60
10 years
18.16
Extreme 18.1608
100.60
More quotes
Managers TitleAgeSince
Founder 64 88-01-07
Chief Executive Officer 71 88-01-07
Director of Finance/CFO 53 02-12-31
Members of the board TitleAgeSince
Director/Board Member 71 10-11-11
Chief Executive Officer 71 88-01-07
Director/Board Member 83 91-05-31
More insiders
Date Price Change Volume
24-07-16 99.06 -1.53% 14
24-07-15 100.6 +1.12% 13
24-07-12 99.49 +1.38% 18
24-07-11 98.14 +1.48% 100
24-07-10 96.71 +0.63% 673

Delayed Quote Sao Paulo, July 16, 2024 at 02:23 pm EDT

More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,095 USD
Average target price
1,063 USD
Spread / Average Target
-2.92%
Consensus